当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Weight changes after adjuvant treatment in Korean women with early breast cancer.

Weight changes after adjuvant treatment in Korean women with early breast cancer.

Abstract：

BACKGROUND:Weight gain is a common problem in breast cancer patients and is reported to be associated with poorer survival. However, most data are limited to Western women. We evaluated weight changes after adjuvant treatment in Korean women with early breast cancer. METHODS:The authors reviewed the records of 260 patients with stage I-III breast cancer treated between June 2003 and February 2006. Body weight, body mass index (BMI) and menopausal status at baseline and after 3, 6, 12 and 24 months of adjuvant treatment were reviewed. RESULTS:Mean patient age was 47.0 years and 61.1% of women were premenopausal. Among them, 195 patients (75.8%) received chemotherapy and 186 (71.5%) received hormonal therapy. Mean baseline weight was 57.5 +/- 9.8 kg and mean BMI was 23.5 +/- 1.6 kg/m(2) (22.8 +/- 3.0 vs. 24.7 +/- 3.2 kg/m(2) for pre- vs. post-menopausal women, P = 0.286). Mean weight changes were; 0.30 kg at 3 months (P = 0.019); 0.16 kg at 6 months (P = 0.367); -0.34 kg at 1 year (P = 0.082); -0.40 kg at 2 years (P = 0.097). Twenty-three patients (10.4%) gained more than 5% of baseline body weight at 1 year, but no clinical variable was found to be associated with these weight gains. CONCLUSION:This study shows that Korean women with early breast cancer do not gain weight after adjuvant treatment. Further studies are needed to determine differences between Asian and Western women in terms of weight changes and prognosis in early breast cancer.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Han HS,Lee KW,Kim JH,Kim SW,Kim IA,Oh DY,Im SA,Bang SM,Lee JS

doi

10.1007/s10549-008-9984-6

subject

Has Abstract

pub_date

2009-03-01 00:00:00

pages

147-53

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

114

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Microcysts and breast cancer: a study of biological markers in archival biopsy material.

    abstract：:Breast cysts are associated with an increased risk of breast cancer. Some biomarkers such as estrogen receptor alpha (ERa), progesterone receptor (PR), and cyclin D1, show similar patterns of expression in epithelial cells lining breast cysts as malignant epithelial cells in local and invasive ductal breast cancer. We...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1019969730552

    authors： Tran DD,Lawson JS

    更新日期：2002-10-01 00:00:00

  • ROCK: a breast cancer functional genomics resource.

    abstract：:The clinical and pathological heterogeneity of breast cancer has instigated efforts to stratify breast cancer sub-types according to molecular profiles. These profiling efforts are now being augmented by large-scale functional screening of breast tumour cell lines, using approaches such as RNA interference. We have de...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0945-5

    authors： Sims D,Bursteinas B,Gao Q,Jain E,MacKay A,Mitsopoulos C,Zvelebil M

    更新日期：2010-11-01 00:00:00

  • PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

    abstract：PURPOSE:Radiotherapy (RT) constitutes an important part of breast cancer treatment. However, triple negative breast cancers (TNBC) exhibit remarkable resistance to most therapies, including RT. Developing new ways to radiosensitize TNBC cells could result in improved patient outcomes. The M2 isoform of pyruvate kinase ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05376-9

    authors： Zhang L,Bailleul J,Yazal T,Dong K,Sung D,Dao A,Gosa L,Nathanson D,Bhat K,Duhachek-Muggy S,Alli C,Dratver MB,Pajonk F,Vlashi E

    更新日期：2019-11-01 00:00:00

  • MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.

    abstract：:Node-positive breast carcinoma is associated with a poor prognosis. Some patients benefit from adjuvant chemotherapy but new treatment modalities should still be developed in order to further increase the cure rate in this patient group. Prognostic factors are needed to define patients for such studies. Here, the prog...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006326513176

    authors： Talvensaari-Mattila A,Pääkkö P,Turpeenniemi-Hujanen T

    更新日期：1999-12-01 00:00:00

  • A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

    abstract：:A dose-response relationship has been suggested for medroxyprogesterone acetate in the treatment of advanced breast cancer. To determine the tolerability and efficacy of increasing doses of megestrol acetate in the treatment of metastatic breast cancer, we conducted a phase I/II study among 57 patients. Three patients...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01990033

    authors： Parnes HL,Abrams JS,Tchekmedyian NS,Tait N,Aisner J

    更新日期：1991-08-01 00:00:00

  • Premature menopause in patients with BRCA1 gene mutation.

    abstract：:This study was undertaken with regard to the gonadotropin theory of ovarian cancer advocated in the literature and was designed to disclose specific features of ovarian morphology in carriers of the BRCA1 gene mutation. We enrolled 171 patients and divided them into two groups: A (n=90)--operated for breast cancer (30...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9220-1

    authors： Rzepka-Górska I,Tarnowski B,Chudecka-Głaz A,Górski B,Zielińska D,Tołoczko-Grabarek A

    更新日期：2006-11-01 00:00:00

  • Erratum to: Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.

    abstract：:Erratum to: Breast Cancer Res Treat (2012),134:549–560,DOI 10.1007/s10549-012-2080-y. In the original publication of the article, Fig. 5c was published incorrectly. The authors apologize for this error and the correct Fig. 5c is given below. ...

    journal_title：Breast cancer research and treatment

    pub_type： 已发布勘误

    doi：10.1007/s10549-016-3703-5

    authors： Tang J,Deng R,Luo RZ,Shen GP,Cai MY,Du ZM,Jiang S,Yang MT,Fu JH,Zhu XF

    更新日期：2016-04-01 00:00:00

  • Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.

    abstract：PURPOSE:We used multiplex immunofluorescence (mIF) to determine whether mitotic rate represents an independent prognostic marker in triple-negative breast cancer (TNBC). Secondary aims were to confirm the prognostic significance of immune cells in TNBC, and to investigate the relationship between immune cells and proli...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05396-5

    authors： Lai CPT,Yeong JPS,Tan AS,Ong CHC,Lee B,Lim JCT,Thike AA,Iqbal J,Dent RA,Lim EH,Tan PH

    更新日期：2019-11-01 00:00:00

  • Quantitation of progesterone receptor mRNA in breast carcinoma by branched DNA assay.

    abstract：:Expression of progesterone receptor (PR) mRNA is indicative of a normal gene regulation mechanism mediated by functional estrogen receptor (ER). A simple assay which can reliably detect and quantitate PR mRNA levels in a small amount of tissue will be of value for studying functional status of ER. We have developed a ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006081127924

    authors： Nargessi RD,Shimizu RM,Xu XM,Connolly J,Zamroud M,Collins ML,Kolberg J

    更新日期：1998-07-01 00:00:00

  • Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

    abstract：BACKGROUND:A multicenter phase II study was conducted to analyze the clinical activity of the steroidal aromatase inhibitor exemestane in the neoadjuvant treatment of post-menopausal women with strongly ER- and/or PgR- positive operable breast cancer. PATIENTS AND METHODS:From September 2000 to December 2003, 80 women...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-007-9843-x

    authors： Mlineritsch B,Tausch C,Singer C,Luschin-Ebengreuth G,Jakesz R,Ploner F,Stierer M,Melbinger E,Menzel C,Urbania A,Fridrik M,Steger G,Wohlmuth P,Gnant M,Greil R,Austrian Breast, Colorectal Cancer Study Group (ABCSG).

    更新日期：2008-11-01 00:00:00

  • Predictors of interobserver agreement in breast imaging using the Breast Imaging Reporting and Data System.

    abstract：:The Breast Imaging Reporting and Data System (BI-RADS) was introduced in 1993 to standardize the interpretation of mammograms. Though many studies have assessed the validity of the system, fewer have examined its reliability. Our objective is to identify predictors of reliability as measured by the kappa statistic. We...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-010-0770-x

    authors： Antonio AL,Crespi CM

    更新日期：2010-04-01 00:00:00

  • Atypical ezrin localization as a marker of locally advanced breast cancer.

    abstract：:Locally advanced breast cancer (LABC) was initially characterized as a large primary tumor (≥5 cm), associated with or without skin or chest-wall involvement, fixed axillary lymph nodes, or disease spread to the ipsilateral internal mammary or supraclavicular nodes. Since 2002, LABC has been reclassified to include sm...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2017-5

    authors： Arslan AA,Silvera D,Arju R,Giashuddin S,Belitskaya-Levy I,Formenti SC,Schneider RJ

    更新日期：2012-08-01 00:00:00

  • Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.

    abstract：:Germline mutations in BRCA1/2 increase the lifetime risk for breast and ovarian cancer dramatically. Identification of such mutations is important for optimal treatment decisions and pre-symptomatic mutation screening in family members. Although current DNA diagnostics is able to identify many different mutations, it ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1016-7

    authors： Joosse SA,Brandwijk KI,Devilee P,Wesseling J,Hogervorst FB,Verhoef S,Nederlof PM

    更新日期：2012-04-01 00:00:00

  • Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation.

    abstract：:Inositol hexaphosphate (IP6) is a naturally occurring polyphosphorylated carbohydrate with demonstrated anti-proliferative and anti-cancer activity in mammary cells. We hypothesized that IP6 modulates cell cycle proteins by action on cytoplasmic signaling molecules. The effects of both pharmacological (2 mM) and physi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-6456-5

    authors： Vucenik I,Ramakrishna G,Tantivejkul K,Anderson LM,Ramljak D

    更新日期：2005-05-01 00:00:00

  • Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US.

    abstract：:Recent breast cancer treatment studies conducted in large urban settings have reported racial disparities in the appropriate use of adjuvant chemotherapy. This article presents the first focused evaluation of black-white differences in receipt and completion of chemotherapy for breast cancer in a primarily rural regio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1916-1

    authors： Lipscomb J,Gillespie TW,Goodman M,Richardson LC,Pollack LA,Ryerson AB,Ward KC

    更新日期：2012-05-01 00:00:00

  • Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

    abstract：:Familial aggregations of breast/ovarian cancer cases frequently depend on BRCA1/2 pathogenic mutations. Here we counselled 120 Italian breast/ovarian cancer families and selected 73 probands for BRCA1/2 mutation screening. Through this analysis we defined the prevalence of BRCA1/2 pathogenic mutations occurring in Ita...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9225-9

    authors： Giannini G,Capalbo C,Ristori E,Ricevuto E,Sidoni T,Buffone A,Cortesi E,Marchetti P,Scambia G,Tomao S,Rinaldi C,Zani M,Ferraro S,Frati L,Screpanti I,Gulino A

    更新日期：2006-11-01 00:00:00

  • Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer.

    abstract：:Fibroblast growth factor receptor 2 is a tyrosine kinase receptor that is a member of the family of individually distinct fibroblast growth factor receptors involved in cell proliferation, invasiveness, motility, and angiogenesis. Genome-wide association studies have identified FGFR2 as a breast cancer (BC) susceptibi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-010-0872-5

    authors： Jia C,Cai Y,Ma Y,Fu D

    更新日期：2010-11-01 00:00:00

  • Measures of energy balance and mammographic density in the Nurses' Health Study.

    abstract：:Mammographic density is a strong risk factor for breast cancer; however the mechanism that underlies this association is unclear. We hypothesized that measures of energy balance early in life and in adulthood may be associated with mammographic density. We conducted a cross-sectional analysis of 1,398 women in the Nur...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9631-7

    authors： Samimi G,Colditz GA,Baer HJ,Tamimi RM

    更新日期：2008-05-01 00:00:00

  • Effect of multiplicity, laterality, and age at onset of breast cancer on familial risk of breast cancer: a nationwide prospective cohort study.

    abstract：:The objective of this nationwide prospective cohort study is to find out the risk of breast cancer (BC) in relatives of patients with multiple BCs by laterality and age at diagnosis of first BC. Having family history of single (HR 1.8; 95 % CI 1.8-1.9) or multiple (HR 2.7; 95 % CI 2.6-2.9) BC was associated with highe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-2848-3

    authors： Kharazmi E,Chen T,Narod S,Sundquist K,Hemminki K

    更新日期：2014-02-01 00:00:00

  • A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.

    abstract：PURPOSE:Among patients diagnosed with breast cancer (BC), women also living with HIV (WLWH) have worse survival than women without HIV. Chronic HIV infection may interfere with the effectiveness of BC treatment, contributing to this disparity. We attempted to determine the impact of HIV infection on response to neoadju...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05889-8

    authors： Nietz S,O'Neil DS,Ayeni O,Chen WC,Joffe M,Jacobson JS,Neugut AI,Ruff P,Mapanga W,Buccimazza I,Singh U,Čačala S,Stopforth L,Phakathi B,Chirwa T,Cubasch H

    更新日期：2020-12-01 00:00:00

  • Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons.

    abstract：:Intraoperative radiotherapy with electrons (ELIOT) after conservative surgery for breast carcinoma was introduced at the IEO in 1999 as a research programme. The results on 1,822 patients treated from January 2000 to December 2008 are reported. Women with unicentric primary breast carcinoma of less than 2.5 cm in the ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1115-5

    authors： Veronesi U,Orecchia R,Luini A,Galimberti V,Zurrida S,Intra M,Veronesi P,Arnone P,Leonardi MC,Ciocca M,Lazzari R,Caldarella P,Rotmensz N,Sangalli C,Sances D,Maisonneuve P

    更新日期：2010-11-01 00:00:00

  • The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines.

    abstract：:Meta-analyses of microarray data indicate that GATA3 is co-expressed with estrogen receptor alpha (ER) in breast cancer cells. While the significance of this remains unclear, it is thought that GATA3 may serve as a prognostic indicator in breast tumors and may play a role in ER signaling. Recently, reciprocal regulati...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0517-8

    authors： Licata LA,Hostetter CL,Crismale J,Sheth A,Keen JC

    更新日期：2010-07-01 00:00:00

  • Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer.

    abstract：:We evaluated the question of whether the chemosensitizers verapamil and quinine given orally to breast cancer patients failing combination chemotherapy alone would result in additional clinical responses. In vitro studies reported here showed verapamil sensitization of Adriamycin resistance in 18.8% of fresh human bre...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1005716214718

    authors： Taylor CW,Dalton WS,Mosley K,Dorr RT,Salmon SE

    更新日期：1997-01-01 00:00:00

  • Circulating tumor cells in non-metastatic triple-negative breast cancer.

    abstract：:Circulating tumor cells (CTCs) can be identified in approximately 25 % of stage I-III breast cancer patients; CTCs presence is a predictor of poor outcome in metastatic breast cancer, but little is known regarding the prognostic significance of CTCs in non-metastatic triple-negative breast cancer (TNBC) patients. The ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3103-7

    authors： Karhade M,Hall C,Mishra P,Anderson A,Kuerer H,Bedrosian I,Krishnamurthy S,Lucci A

    更新日期：2014-09-01 00:00:00

  • Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network.

    abstract：PURPOSE:Clinical trials demonstrated adjuvant aromatase inhibitor treatment is superior for decreasing breast cancer recurrence risk over adjuvant tamoxifen treatment as early as 2001. Yet clinical use for adjuvant treatment was not recommended by the American Society of Clinical Oncology until 2004. Aromatase inhibito...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9558-z

    authors： Aiello EJ,Buist DS,Wagner EH,Tuzzio L,Greene SM,Lamerato LE,Field TS,Herrinton LJ,Haque R,Hart G,Bischoff KJ,Geiger AM

    更新日期：2008-02-01 00:00:00

  • A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family.

    abstract：:We report a novel germline 5369delATTT mutation in BRCA2 gene, detected in a 45-year-old woman with bilateral breast cancer. This deletion was also detected in her father with prostatic cancer and her sister with breast cancer. The mutation originates a premature stop at codon 1723 of BRCA2 protein and has not been do...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0361-x

    authors： Salgado J,Aramendía JM,Gutierrez C,Gil C,Robles M,García-Foncillas J

    更新日期：2010-05-01 00:00:00

  • Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway.

    abstract：:M1775R and A1789T are two missense variants located within the BRCT domains of BRCA1 gene. The M1775R is a known deleterious variant, while the A1789T is an unclassified variant that has been analyzed and classified as probably deleterious for the first time by our group. In a previous study, we described the expressi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2705-9

    authors： Guglielmi C,Cerri I,Evangelista M,Collavoli A,Tancredi M,Aretini P,Caligo MA

    更新日期：2013-10-01 00:00:00

  • Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.

    abstract：INTRODUCTION:Since older patients with breast cancer are underrepresented in clinical trials, an oncogeriatric approach is advocated to guide treatment decisions. However, the effect on outcomes is unclear. The aim of this study was to compare treatments and outcomes between patients treated in an oncogeriatric and a s...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05860-7

    authors： de Boer AZ,van de Water W,Bastiaannet E,de Glas NA,Kiderlen M,Portielje JEA,Extermann M

    更新日期：2020-11-01 00:00:00

  • Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

    abstract：:Metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. We report results of a neoadjuvant "window of opportunity" study of metformin in women with operable breast cancer. Newly diagnosed, untreated, non-diabetic breast cancer patients received metformin ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-012-2223-1

    authors： Niraula S,Dowling RJ,Ennis M,Chang MC,Done SJ,Hood N,Escallon J,Leong WL,McCready DR,Reedijk M,Stambolic V,Goodwin PJ

    更新日期：2012-10-01 00:00:00

  • Learning to predict relapse in invasive ductal carcinomas based on the subcellular localization of junctional proteins.

    abstract：:The complexity of breast cancer biology makes it challenging to analyze large datasets of clinicopathologic and molecular attributes, toward identifying the key prognostic features and producing systems capable of predicting which patients are likely to relapse. We applied machine-learning techniques to analyze a set ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0557-0

    authors： Asgarian N,Hu X,Aktary Z,Chapman KA,Lam L,Chibbar R,Mackey J,Greiner R,Pasdar M

    更新日期：2010-06-01 00:00:00